News OEM
Biomaterials for Osteocalcin immunoassay development & manufacturing
March 27, 2024
Osteocalcin is a small protein composed by 49 amino acids and is also known as bone gamma-carboxylation.
Osteocalcin is the most abundant non-collagenous protein in bone and is synthesized by mature osteoblasts, odontoblasts, and hypertrophic chondrocytes. The main role of osteocalcin is in metabolic regulation, bone mineralization and calcium ion homeostasis1.
In clinical laboratories, serum levels of osteocalcin are considered a marker of osteoblast function for the assessment of bone formation2 and, alongside other parameters, may be useful for assessing osteoporosis1. Osteoporosis is a clinical condition that can lead to impaired bone strength and loss of bone mass, increasing the risk of fractures due to the deterioration of bone tissue and disruption of bone microarchitecture3. Osteoporosis is the most common bone disease in humans, with an estimated worldwide prevalence of 18.3%4.
How Werfen can support you
We can support your immunoassay portfolio expansion in the bone metabolism panel by providing antibodies for the development and manufacturing of immunoassays to determine Osteocalcin.
Werfen Bone metabolism biomaterials portfolio consists of the following products
Biomaterial | PN | Product Description |
Antibody | 3000-7072 | Anti-Osteocalcin mAb (OST18m) |
3000-7073 | Anti-Osteocalcin mAb (OST24m) |
Contact us for further information on product availability and development stage
[1] Rong Kuo et al. Bone biomarker for the clinical assessment of osteoporosis: recent developments and future perspectives. Biomarker Research. 2017
[2] Jinqiao et al. An overview of osteocalcin progress. The Japanese Society for Bone and Mineral Research. 2016
[3] Sözen et al. An overview and management of osteoporosis. European Journal of Rheumatology. 2016
[4] Salari et al. The global prevalence of osteoporosis in the world: a comprehensive systematic review and meta-analysis. 2021
NEWS
Latest News
October 24, 2024
September 27, 2024
August 6, 2024
Please contact us directly via telephone or with the following form.
Tel. +34 93 860 90 00